489 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
related to decrease in unrecognized tax benefits (5)
Tax expense related to increase in valuation allowance (6)
Excess tax benefit (shortfall) from … in Primrose Bio
Other (4)
Income tax effect of adjusted reconciling items above
Tax benefit related to decrease in unrecognized tax benefits (5)
Tax
8-K/A
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
9 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
9:48pm
not achieve the intended strategic, operational and financial benefits; and ongoing or future litigation could expose Ligand to significant liabilities … , operating losses from Novan since the acquisition date, as well as gain on debt extinguishment in the prior year period.
(5) Excess tax benefits from share
8-K
EX-99.1
rjuy eladnabl
8 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
4:08pm
8-K
EX-10.1
nrmqkygj8k31
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
8-K
376 8g0xb9
18 Sep 23
Other Events
5:26pm
8-K
EX-99.1
e3a80kvcrs12jv1ytyl
8 Aug 23
Ligand Reports Second Quarter 2023 Financial Results
4:02pm
8-K
EX-99.1
8o8a0j
4 May 23
Ligand Reports First Quarter 2023 Financial Results
4:06pm
8-K
s0wsgn5 sw3m1ws
5 Dec 22
Departure of Directors or Certain Officers
7:03am
8-K
EX-99.1
9lkgxci2tdhsd0p5
7 Nov 22
Ligand Reports Third Quarter 2022 Financial Results
4:04pm
8-K
2y9u8
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm